Ignite Creation Date:
2025-12-24 @ 11:51 PM
Ignite Modification Date:
2026-01-18 @ 12:12 PM
Study NCT ID:
NCT06190951
Status:
RECRUITING
Last Update Posted:
2025-11-19
First Post:
2023-11-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Sponsor:
Regeneron Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
R3767-ONC-2208
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None